- Home
- INO vs CCIF Comparison
INO vs CCIF Comparison
Compare INO & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | INO | CCIF |
|---|---|---|
| Founded | 1979 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.1M | 101.1M |
| IPO Year | 1998 | N/A |
Fundamental Metrics
Financial Performance| Metric | INO | CCIF |
|---|---|---|
| Price | $1.58 | $4.04 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 76.9K |
| Earning Date | 03-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 25.90% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $182,337.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23,060.18 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $7.43 |
| 52 Week High | $2.98 | $10.16 |
Technical Indicators
Market Signals| Indicator | INO | CCIF |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 34.04 |
| Support Level | $1.54 | $3.97 |
| Resistance Level | $1.78 | $4.20 |
| Average True Range (ATR) | 0.11 | 0.17 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 32.79 | 30.04 |
Price Performance
Historical ComparisonAbout INO Inovio Pharmaceuticals Inc.
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.